Use your antibodies-online credentials, if available.
Il n’y a pas de produits dans votre liste de comparaison.
Votre panier est vide.
Afficher toutes les espèces
Afficher tous les synonymes
Sélectionnez vos espèces et l'application
anti-Human SPRY1 Anticorps:
anti-Rat (Rattus) SPRY1 Anticorps:
anti-Mouse (Murine) SPRY1 Anticorps:
Vous arrivez à notre recherche pré-filtrée.
Human Monoclonal SPRY1 Primary Antibody pour IHC (p), ELISA - ABIN564437
Moghaddam, Amini, Wei, Pourgholami, Morris: Initial report on differential expression of sprouty proteins 1 and 2 in human epithelial ovarian cancer cell lines. dans Journal of oncology 2012
Show all 2 Pubmed References
Human Polyclonal SPRY1 Primary Antibody pour ELISA, WB - ABIN564436
Mekkawy, De Bock, Lin, Morris, Wang, Pourgholami: Novel protein interactors of urokinase-type plasminogen activator receptor. dans Biochemical and biophysical research communications 2010
Human Polyclonal SPRY1 Primary Antibody pour ELISA, IHC - ABIN4355747
Hanafusa, Torii, Yasunaga, Matsumoto, Nishida: Shp2, an SH2-containing protein-tyrosine phosphatase, positively regulates receptor tyrosine kinase signaling by dephosphorylating and inactivating the inhibitor Sprouty. dans The Journal of biological chemistry 2004
Study demonstrated that Spry1 has a role in supporting mitogen-induced vascular hyperplasia, at least in part by promoting Akt (Montrer AKT1 Anticorps)/Rb signaling and increasing mitogen-induced cyclinD1 expression and decreasing p27Kip1 (Montrer CDKN1B Anticorps) expression.
SPRY1 maybe a negative feedback regulator in normal human epidermal keratinocytes.
FREM2 (Montrer FREM2 Anticorps) is thus proposed as a novel GB biomarker and a putative biomarker of glioblastoma stem cells. Both FREM2 (Montrer FREM2 Anticorps) and SPRY1 are expressed on the surface of the GB cells, while SPRY1 alone was found overexpressed in the cytosol of non-malignant astrocytes.
Inhibition of miR (Montrer MLXIP Anticorps)-29b could attenuate atherosclerosis by inhibiting the SPRY1/MAPK (Montrer MAPK1 Anticorps) signaling pathway and inflammation in aorta.
During adipogenesis and osteogenesis, TNF-alpha (Montrer TNF Anticorps) significantly increased Spry1 levels and overexpression of miR (Montrer MLXIP Anticorps)-21 dramatically decreased Spry1 levels in the presence of TNF-alpha (Montrer TNF Anticorps), indicated important roles of miR (Montrer MLXIP Anticorps)-21 in modulating link between TNF-alpha (Montrer TNF Anticorps) and Spry1. Our findings introduce a molecular mechanism in which TNF-alpha (Montrer TNF Anticorps) suppresses adipogenic and osteogenic differentiation of PDLSCs by inhibiting miR (Montrer MLXIP Anticorps)-21/Spry1 func...
Although the expression of SPRY1 was low when compared with other tumors, SPRY1 was variably expressed in primary Ewing sarcoma tumors and higher expression levels were significantly associated with improved outcome in a large patient cohort.
SPRY1 and SPRY2 (Montrer SPRY2 Anticorps) mRNA transcripts were significantly upregulated in human CRC (Montrer CALR Anticorps). Suppression of SPRY2 (Montrer SPRY2 Anticorps) repressed AKT2 (Montrer AKT2 Anticorps) and EMT (Montrer ITK Anticorps)-inducing transcription factors and significantly increased E-cadherin (Montrer CDH1 Anticorps) expression. Concurrent downregulation of SPRY1 and SPRY2 (Montrer SPRY2 Anticorps) also increased E-cadherin (Montrer CDH1 Anticorps) and suppressed mesenchymal markers in colon cancer cells.
Spry1 plays a selective role in at least a subset of triple-negative breast cancer to promote the malignant phenotype via enhancing EGF (Montrer EGF Anticorps)-mediated mesenchymal phenotype.
Suppression of SPRY1 by age-associated methylation inhibits the replenishment of the muscle stem cell pool.
Cosuppression of Sprouty and Sprouty-related negative regulators of FGF signalling in prostate cancer
Loss of Spry1/2 enhances the survival of effector CD8 (Montrer CD8A Anticorps)+ T cells and results in the formation of more protective memory cells. Deleting Spry1/2 in antigen-specific CD8 (Montrer CD8A Anticorps)+ T cells may have therapeutic potential for enhancing the survival and functionality of effector and memory CD8 (Montrer CD8A Anticorps)+ T cells in vivo.
The results show that lnc-Spry1 could act as an early mediator of TGF-beta (Montrer TGFB1 Anticorps) signaling and reveal different roles for a long noncoding RNA in modulating transcriptional and posttranscriptional gene expression.
modulation of stromal paracrine signaling and extracellular matrix remodeling by SPRY1 regulates mammary epithelial morphogenesis during postnatal development.
Here, we present a novel mouse model of pheochromocytoma consisting of double-heterozygous mice for Pten and Sprouty1 (Spry1), which leads to pheochromocytomas that appear at earlier onset and grow at a higher rate than those from Pten+/- mice.
Sprouty gain of function disrupts lens cellular processes and growth by restricting receptor tyrosine kinase (Montrer ERBB3 Anticorps) signaling.
In vivo analysis of thyroid glands from Spry1 knockout mice reveals that Spry1 induces a senescence-associated secretory phenotype via activation of the NFkappaB pathway.
showed that hSpry1 overexpression prevents VEGF (Montrer VEGFA Anticorps) secretion
May function as an antagonist of fibroblast growth factor (FGF) pathways and may negatively modulate respiratory organogenesis.
protein sprouty homolog 1
, sprouty, Drosophila, homolog of, 1 (antagonist of FGF signaling)
, sprouty 1 protein
, sprouty homolog 1, antagonist of FGF signaling (Drosophila)
, sprouty homolog 1, antagonist of FGF signaling
, sprouty 1
, sprouty homolog 1a, antagonist of FGF signaling
, sprouty homolog 1b, antagonist of FGF signaling
, inhibitor of receptor tyrosine kinases